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Introduction
Tissue-specific gene delivery using receptor-mediated endocytosis was first demonstrated by Wu and Wu 1 who used the asialoglycoprotein receptor localised in hepatocytes to deliver the chloramphenicol acetyltransferase reporter gene to rat liver. In these studies, the investigators ligated asialoglycoprotein to polylysine which then was ionically bound to DNA to form a complex that bound to and was internalised by the asialoglycoprotein receptor. Other investigators have used transferrin, 2 folic acid 3 or epidermal growth factor 4 in a similar manner to target specific cells. A major disadvantage of large proteins as targeting molecules is the abundance of material required to synthesise sufficient quantities of complex for effective gene delivery in humans. We have investigated the possibility of utilising small peptides that bind to specific receptors as a means of gene delivery. They have considerable advantage in that they can be readily synthesised and they are less likely to be antigenic in vivo. However, small peptides also can be easily disrupted by chemical modification leading to little or no receptor binding activity.
The carboxy terminal octapeptide of cholecystokinin (CCK 8 ) is a hormone that binds cell surface receptors found in high density in the pancreas and also reported to be associated with a number of pancreatic tumours. We have attempted to construct a gene delivery system capable of directing foreign DNA to cholecystokinin receptor-positive cells with the long-term view of developing effective gene therapy protocols. Apart from pancreatic cancers which mostly arise in exocrine cells, gene therapy directed towards CCK receptor positive cells may be important for ongoing trials for cystic fibrosis where pancreatic insufficiency is a major complication due to the lack of functional CFTR. There also are many inherited and congenital disorders of the pancreas which, while individually may be uncommon, collectively they represent a significant human health problem.
Our initial task involved the synthesis of a CCK 8 -DNA complex that retained receptor-binding capacity. Complexes formed by ligating CCK 8 to polylysine in a manner similar to that reported elsewhere 1 resulted in a conjugate with little or no binding to rat pancreatic acinar cells. Polylysine appeared to destabilise CCK 8 possibly disrupting the folding of the hormone. NMR and fluorescence-transfer measurements have indicated that CCK 8 is folded with ␤ and ␥ turns around the Gly-Trp-MetAsp and Met-Asp-Phe-NH 2 sequences, respectively. 6 These folds appear to be stabilized by intramolecular ionic interactions involving the ␤-carboxyl group of the aspartate adjacent to the carboxy-terminal phenylalanine. 7 We therefore investigated several other techniques for associating CCK 8 with DNA that would not inhibit receptor binding and internalisation.
We report here an alternative approach to forming peptide-DNA complexes using avidin-biotin chemistry based upon the method of Pardridge and associates, 8, 9 who have successfully ligated small oligonucleotides to avidin for transcellular delivery both in vitro and in vivo. We have further modified the avidin-DNA conjugate to include CCK 8 bound via surface primary amines generating a CCK 8 -avidin-biotin-DNA complex and herein show that this complex retains receptor binding capacity both in vitro and in vivo.
Results
The overall scheme for the synthesis of the CCK 8 -DNA complex is shown in Figure 1 . Modification of CCK 8 with N-succinimideyl-3-(2-pyridyldithio)proprionate (SPDP) took advantage of the single primary amine located at the N-terminus of the peptide. This resulted in only one substitution product (CCK 8 -PDP) which was purified by HPLC. Avidin was also modified with SPDP, reduced at pH 4 generating avidin-SH by removing the thiopyridyl group with minimal disruption to intramolecular dithiols, and subsequently purified by size exclusion chromatography. Increasing the molar ratio of SPDP to avidin up to 10, resulted in a linear increase in the number of SPDP substitutions without loss in biotin binding. However at higher ratios, a significant loss in binding was seen. This probably results from modification of the relatively inaccessible lysine located in the biotin-binding pocket of avidin, which previously has been shown to be essential for biotin affinity. 10 Routinely, a 10-fold molar excess of SPDP was used.
Conjugation of CCK 8 -PDP to avidin-SH was achieved by thiol exchange in phosphate buffer, pH 7.5, at room temperature overnight. In the presence of excess CCK 8 -PDP, the reaction went to near completion under these conditions resulting in a final molar ratio of CCK 8 to avidin of 8:1.
To attach the CCK 8 -avidin conjugate to DNA, the pSV-CAT vector was linearised with BglII generating a 5′ overhang at each end. By endfilling with Klenow fragment in the presence of biotin-11-dUTP, two biotin molecules were incorporated into each DNA molecule. BglII was chosen because it cleaved the vector at a site distant from the chloramphenicol acetyltransferase (CAT) gene. Figure 2 shows the electrophoretic mobility of biotinylated DNA in the presence of increasing molar ratios of CCK 8 -avidin. Little difference in mobility was observed at low molecular ratios but by 10 to 30:1, the DNA migrated more slowly. This probably resulted from nonspecific binding of the cationic avidin to the DNA. When transblotted on to nitrocellulose and probed for unbound biotin, it was seen that a molar excess of between 2 and 4 was required to completely bind the DNA-associated biotin. Although avidin can bind up to four molecules of biotin, these results suggest that each avidin molecule binds at most one DNA-biotin molecule. Steric hindrance by the DNA may prevent further binding once the first biotin molecule occupies a binding site.
To determine the receptor binding capacity of CCK 8 and its derivatives, competition for 125 I-CCK 8 uptake by rat pancreatic acini was measured. Figure 3 shows that more than 90% of 125 I-CCK 8 uptake could be inhibited by 1 m CCK 8 . CCK 8 -PDP blocked 125 I-CCK 8 uptake by almost 95% indicating that modification of the peptide with SPDP did not affect receptor binding capacity. Similarly, 100 nm CCK 8 -avidin conjugate reduced CCK 8 uptake to the same extent as a similar concentration of the peptide itself. However, neither avidin-SH nor biotinylated DNA affected peptide binding. These results show that conjugation of CCK 8 to avidin retained binding capacity to the rat pancreatic cholecystokinin receptor.
To determine uptake of the CCK 8 -DNA complex by rat pancreatic acini, cells were incubated with 50 pm 32 Pcomplex for up to 4 h ( Figure 4 ). Uptake of complex increased with time reaching 5-6 fmol/mg protein. In the presence of excess CCK 8 , uptake of complex was significantly diminished although not completely abolished (Table 1) . Similarly, uptake was inhibited when the incubations were carried out at 4°C (Table 1) . Cell-associated radiolabel could not be removed by washing the acini in acetate buffer (pH 2.5 containing 500 mm NaCl) which rapidly dissociates surface CCK 8 from its receptor. 11 These results suggest that the complex was internalised following binding to the CCK receptor. When 32 P-complex was administered intra-arterially to anaesthetised rats, it was rapidly cleared from the circulation such that, by 5 min, little or no intact plasmid was detectable ( Figure 5 ). The total body clearance for the complex was 14 ml/min with an apparent volume of distribution of 53 ml. The half-life was only 2.6 min. This rapid clearance suggested either that the complex was degraded in the plasma compartment or that it was Rat pancreatic acini were incubated with 50 pm 32 P-complex for 60 min at 37°C (control) or at 4°C. CCK 8 (1 m) was added to some cells to determine nonspecific binding. At the end of the experiment, cells were washed with acetate buffer (pH, 2.5) according to the method of Menozzi et al. 11 Results are expressed as mean ± s.e.m., n = 3. highly extracted across the liver which has been shown previously to remove DNA from the circulation via the scavenger receptor system. 12 Incubation of complex with plasma in vitro for up to 60 min showed no evidence of degradation suggesting that plasma DNases were not a major cause of complex degradation in vivo (data not shown). However, when polyinosinic acid, an inhibitor of the hepatic scavenger receptor system, 13 was coadministered with the complex, clearance decreased to 1.2 ml/min and the half-life increased to 10 min. These results indicate that extraction across the liver was the principle route of removal of complex from the circulation. Figure 6a shows the tissue distribution of radiolabel 20 min after an intra-arterial dose of complex. High levels of radioactivity were seen in the liver but very little in the pancreas (Ͻ0.1% of dose) or other cholecystokinin receptor positive tissues. Distribution of avidin-DNA was similar to that for the complex (Figure 6c ). When polyinosinic acid was co-administered with the complex, a slight increase in distribution to the pancreas was seen although this was not statistically significant (Figure 6b ). Tissue distribution of total radiolabel at longer times (90 min) showed even less uptake in the peripheral tissues (data not shown).
Following intraperitoneal administration of the complex, distribution to most major tissues in the body was low and generally decreased with time up to 72 h ( Figure 7 ). By contrast, there was a significant accumulation of radiolabel in the pancreas after 24 h accounting for between 5 and 8% of the total dose. No accumulation
Figure 7 Distribution of radiolabel to tissues following intraperitoneal administration of complex. In the upper panel, 2.5 Ci of CCK-avidin-DNA were administered intraperitoneally to rats and the distribution of radiolabel was determined in the pancreas (᭹), liver (᭺), lung (), duodenum (ᮀ) and brain (̄). In the lower panel, the distributions of avidin-DNA and CCK-avidin-DNA (complex) to the pancreas are compared.
Results are mean ± s.e.m., n = 3.
was observed in other tissues in the peritoneal cavity such as the duodenum or liver. When avidin-DNA was administered intraperitoneally, a marked decrease in accumulation of radiolabel in the pancreas was seen indicating that the CCK 8 moiety of the complex was necessary for targeting ( Figure 7 ).
Discussion
Gene delivery to target cells in vivo remains a major limitation for efficient and practical human gene therapy. At present, gene delivery is achieved either by ex vivo transfection of a host cell, direct injection, liposome-based delivery or receptor-mediated delivery.
14 This latter approach takes advantage of binding and internalisation of receptor systems on the surface of target cells. We have been interested in whether small peptides could be utilised to direct foreign DNA to target cells in vivo and have reported here the use of avidin-biotin ligation to bind CCK 8 to DNA. Modification of CCK 8 with SPDP did not affect receptor binding although subsequent ligation to polylysine did. However, CCK 8 ligated to avidin retained receptor binding capacity as did the CCK 8 -avidin-biotin-DNA complex. The complex also appeared to be internalised as it could not be removed by acid wash. Avidin has been shown to facilitate the uptake of oligonucleotides because of its cationic nature. 8 Whether this characteristic is retained after modification with SPDP is not yet known. However, in rat pancreatic acini, we found that approximately 30% of total binding was nonspecific (not inhibited by excess CCK 8 ) suggesting that avidin may have contributed to some of the binding.
When complex was administered intra-arterially, no targeting was observed to any cholecystokinin receptor positive tissues including the pancreas. Macromolecules in the circulation must transverse the endothelial cell barrier for access to parenchymal cells and this barrier may be sufficient to hinder targeting. Once in the circulation, the complex was rapidly removed by the scavenger receptors in the liver. Again, this rapid clearance will limit distribution to peripheral organs, especially to those tissues with relatively small blood flows. The blood flow to the pancreas is less than 2% of total cardiac output. 15 The targeting of the pancreas following intraperitoneal administration of the complex provides a practical route for DNA delivery. How the complex was transported from the peritoneal cavity to the pancreas remains unknown. It may have had sufficient access to receptorpositive cells by simple diffusion across the surface of the organ although the lack of accumulation in the GI tract, which contains both CCK and gastrin receptors, suggests that simple diffusion is unlikely. Alternatively, the extensive lymphatic system of the pancreas may have contributed to targeted delivery. If so, then intraperitoneal administration may also deliver foreign DNA to pancreatic tumour cells that initially spread via the lymphatics. Further work is required to determine the exact delivery path of the CCK 8 -DNA complex.
While the current investigation has focused on the pharmacokinetics of the CCK 8 -DNA complex, the level of reporter gene expression was measured in some experiments. However, we were unable to detect any CAT activity either in vitro or in vivo. pSV-CAT transcript was occasionally observed by RT-PCR but the amount was variable between experiments and more often it was not observed at all. This apparent lack of expression may be due to insufficient DNA delivery or delivery to an inappropriate intracellular compartment, as well as the general lack of expression of plasmid DNA in nonproliferative tissues. Several studies that have demonstrated receptor-dependent gene delivery have also shown that formation of tightly condensed toroid structures is important for optimum expression. 16, 17 We are currently investigating the effects of condensing the complex with histones on receptor binding, internalisation and subcellular distribution. Moreover, since many studies have shown that receptor-mediated gene delivery and expression can be enhanced with replication-deficient adenoviruses, [18] [19] [20] we are also investigating the distribution of CCK 8 -DNA-adenovirus complexes. These studies may assist in optimising gene expression both in vitro and in vivo.
Materials and methods
Materials CCK 8 containing a sulfated tyrosine was purchased from Auspep (Melbourne, Victoria, Australia), N-succinimideyl-3-(2-pyridyldithio)proprionate was purchased from Pierce (Rockford, IL, USA), pSV-CAT and Wizard resin were obtained from Promega (Annadale, NSW, Australia), and radiochemicals were purchased from Amersham (Buckinghamshire, UK). Biotin-11-dUTP, polyinosinic acid and avidin were obtained from Sigma (St Louis, MO, USA). All other chemicals were of the highest purity available.
Synthesis of CCK 8 -avidin conjugates CCK 8 was dissolved in 100 mm phosphate buffer containing 100 mm NaCl at pH 7.5 and reacted overnight at 37°C with a four-fold molar excess of SPDP. The resulting product 3-(2-pyridyldithio)propionyl-CCK 8 (CCK 8 -PDP) was purified by HPLC using a C 18 reverse phase column. The product was eluted with a mobile phase gradient of 20% acetonitrile, 0.1% trifluoroacetic acid in water to 80% acetonitrile, 0.1% trifluoroacetic acid in water over 10 min. CCK 8 -PDP was collected and lyophilised. Under these conditions, substitution was essentially complete with Ͼ95% recovery.
Avidin was reacted with up to 10-fold molar excess of SPDP at 37°C for 45 min in 100 mm phosphate buffer, pH 7.5, containing 100 mm NaCl. The resulting avidin-PDP was desalted on a BioRad P6 column (BioRad Laboratories, Regents Park, NSW, Australia) and the recovery of protein (65-70%) determined by the method of Bradford. 21 The degree of substitution was determined by the release of pyridine-2-thione in the presence of dithiothreitol at a wavelength of 343 nm assuming an extinction coefficient of 8.08 × 10 3 m/cm. The CCK 8 -avidin conjugate was formed by thiol exchange. Avidin-PDP was reduced with 50 mm dithiothreitol for 5 min at pH 4 and desalted twice into phosphate buffer, pH 7.5. A 16-fold molar excess of CCK 8 -PDP was then added and incubated at room temperature overnight. The resulting CCK 8 -avidin conjugate was desalted and protein content determined. The amount of CCK 8 bound to avidin was quantified by HPLC following reduction with 2-mercaptoethanol. The conjugate was stored at 4°C until used.
Biotinylation of pSV-CAT pSV-CAT control vector was linearised with BglII endonuclease and deproteinated on Wizard DNA purification resin. The DNA was biotinylated by incubating 2 pmol (62 g) of linearised pSV-CAT with 60 U Klenow fragment, 200 pmol of dGTP and dATP, 40 pmol biotin-11-dUTP and 4 pmol ␣-32 P-dCTP at 37°C for 90 min. The DNA was purified on Wizard DNA purification resin and quantified by fluorescence using bis-benzimide H 33258 as described elsewhere. 22 The specific activity of the resulting 32 P-pSV-CAT was 10.9 Ci/mmol.
Synthesis of CCK 8 -DNA complexes
Biotinylated pSV-CAT was incubated in 50 mm ammonium carbonate containing 500 mm NaCl (pH 11) with up to 30-fold molar excess CCK 8 -avidin at 37°C for 30 min. The complex was analysed by electrophoresis through 0.8% agarose at 80 V for 60 min and visualised by ethidium bromide staining. The agarose gels were also transblotted on to nitrocellulose and the presence of unbound DNA-associated biotin was detected using peroxidase-labelled avidin.
Binding of CCK 8 -DNA to rat pancreatic acini Rat pancreatic acini were isolated by a method adapted from Menozzi et al. 11 Male Sprague-Dawley rats (5-6 weeks) were anaesthetised with 150 mg/kg pentobarbital intraperitoneally and the pancreas removed. The pancreas was washed and incubated at 37°C in collagenase (0.5 mg/ml) and hyaluronidase (1 mg/ml) in Ringer's solution for 20 min. The cell digest was passed through a 19-gauge needle, filtered through 100 nylon mess and washed twice with Ringer's solution. Cell viability was assessed by Trypan Blue exclusion.
The binding of CCK 8 -PDP and CCK 8 -avidin to cholecystokinin receptors was determined by competitive binding assays using 125 I-labelled CCK 8 . Acini (3-5 mg protein/ml) were incubated with 50 pm 125 I-CCK 8 for 2 h at 37°C in Ringer's solution containing 0.5% bovine serum albumin in the presence and absence of CCK 8 conjugates. At the end of the incubation, the cells were rapidly centrifuged at 15 000 g for 10 s through di-n-butyl phthalate to separate bound and free hormone. Cellassociated radioactivity was quantified in a Packard 5650 gamma counter (Packard Instruments, Downers Grove, IL, USA) and standardised to total protein content.
The uptake of CCK 8 -DNA by rat pancreatic acini was determined by incubating cells (3-5 mg total protein/ml) with 50 pm complex for up to 240 min. At various times, cell-associated radioactivity was measured as described above.
In vivo pharmacokinetics and tissue distribution of complex For intra-arterial administration, rats received a bolus dose of complex or avidin-DNA (1 Ci in 200 l saline) via a cannula placed in the carotid artery of anaesthetised male Spague-Dawley rats. Blood samples were collected at various times up to 20 min after which the animals were killed and tissues collected. Following homogenisation of tissues in water, an aliquot of each was taken and 32 P content determined by liquid scintillation spectroscopy. All of the radiolabel in the blood was present in the plasma compartment. After determining the total radioactivity in each plasma sample, aliquots were subjected to agarose gel electrophoresis to quantify intact and degraded plasmid. The gels were cut into 5 mm slices and radiolabel content determined.
For intraperitoneal administration, rats received 2.5 Ci complex in 2 ml water. At various times up to 72 h, animals were killed and the peritoneal cavity was lavaged twice with 5 ml saline. Tissues were collected and processed as described above.
